Investment goal: Capital growth
Target holding period: 7 years
The objective of the Fund is to invest in a balanced portfolio of early-stage life science businesses with the aim of generating an excellent return for Investors. By doing this we will help to create and grow some exciting, innovative and potentially life changing companies. The businesses the Fund will invest in may have an impact on their local economy, providing highly skilled jobs and further increasing the overall strength of the UK life sciences sector.
A team of venture builders and WAPG’s network of science infrastructure across the UK provide privileged access to a stream of validated investment opportunities. Our sites and venture development activity act as funnels, drawing in the best opportunities in the area.
WAPG will be working with opportunities from various sources including ICURe, Oxford and East Midlands AHSN Accelerators, Scottish University Accelerator, Scottish Universities Accelerator, Scottish High Growth Programme, Pharma Partners, WAPG's own network.
Founded in 2016, and derived from frontline clinical experience, BiVictriX is a rapidly emerging biotechnology company applying a novel approach to develop safer, more effective cancer therapies.
Based at BioCity Nottingham, XenoGesis specialises in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis, in vitro pharmacology, DMPK due diligence and modelling and simulation, and has worked directly on the predictions of human PK and dose for eight compounds that have entered clinics.
Roylance Pharma is a provider of biobanking and stability storage facilities to store pharmaceutical and biological samples.